GeneSys Biologics is dedicated to the development of affordable insulin biosimilars, addressing the growing global challenge of diabetes. The company employs a comprehensive approach to accelerate the development of these biosimilars, focusing on core competencies such as development, scale-up, technology transfer, and manufacturing. By leveraging their scientific expertise and collaborating with partners for commercialization, GeneSys aims to simplify the supply chain and ensure that insulin remains accessible to all patients in need. Their mission is driven by the belief that no one should be left behind due to the high costs associated with insulin.

The company's pipeline includes a range of insulin analogues designed to meet the needs of insulin-dependent diabetes patients worldwide. Their products encompass long-acting, short-acting, and rapid-acting insulins, all developed in accordance with stringent scientific, technical, and regulatory standards. Notable biosimilars in their portfolio include GEN1501, a long-acting insulin glargine; GEN1504, a rapid-acting insulin lispro; GEN1503, a rapid-acting insulin aspart; and GEN1502, a short-acting human insulin. GeneSys Biologics is committed to ensuring that these high-quality, safe, and affordable insulin options are available to improve glycemic control for both adults and children with diabetes.

India

GeneSys Biologics was established in Nov 2014 by a group of like-minded individuals with strong global experience in development of biosimilars. 

A science-based biosimilar company with the vision of becoming one of the leading global biopharmaceutical companies in the world. 

GeneSys aims to expand market access across the globe by providing affordable and high quality biosimilars.

4th Floor, Bhaskar Plaza, Road no 1 Banjara Hills, Hyderabad, Telangana 500034, IN

GeneSys Biologics

Company Details